GENinCode Plc Reports 25% Revenue Boost and Expands Footprint in US Market

GENinCode Plc (LSE:GENI) has announced a 25% rise in revenue for the fiscal year 2024, driven by strong growth across the UK and European markets, alongside its initial commercial foray into the United States. The company began generating US revenues from its LIPID inCode and CARDIO inCode polygenic testing products, with CARDIO inCode recently receiving a Notice of Allowance for patent protection in the US.

In the UK, the NHS has expanded the use of LIPID inCode for diagnosing familial hypercholesterolemia, while a CARDIO inCode pilot program was launched in Spain. To fuel further growth and commercialization, GENinCode successfully raised £4.1 million through a secondary share placement.

Looking ahead to fiscal 2025, GENinCode aims to accelerate revenue growth, enhance profit margins, and progress toward breakeven. The company plans to deepen its commercial presence in the US market while continuing to develop its programs within the NHS and broader European healthcare systems.

About GENinCode

Based in the UK, GENinCode Plc specializes in genetic risk assessment technologies targeting cardiovascular disease and ovarian cancer. Leveraging a blend of clinical algorithms and AI-driven bioinformatics, the company delivers predictive tools designed to improve patient risk stratification and support proactive healthcare decision-making across the UK, Europe, and the United States.

CLICK HERE TO REGISTER FOR FREE ON ADVFN, the world's leading stocks and shares information website, provides the private investor with all the latest high-tech trading tools and includes live price data streaming, stock quotes and the option to access 'Level 2' data on all of the world's key exchanges (LSE, NYSE, NASDAQ, Euronext etc).

This area of the ADVFN.com site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of ADVFN Ltd. ADVFN Ltd does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at ADVFN.com is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by ADVFN.COM and is not intended to be relied upon by users in making (or refraining from making) any investment decisions. Authors may or may not have positions in stocks that they are discussing but it should be considered very likely that their opinions are aligned with their trading and that they hold positions in companies, forex, commodities and other instruments they discuss.

Comments are closed

WHAT IS ADVFN?

ADVFN covers all things stock market.

From the news and opinion pieces on pages like this to share discussion forums, charting tools, financials, live share prices and Level 2, order book data

If you trade or invest ADVFN has the tools you need to make the right decisions.

• 

  101 Ways to Pick Stock Market Winners

  You need the number one bestselling investment guide, the definitive text for day traders, investors and stock pickers.

• 

  The Death of Wealth

  Dissecting the global economy and the financial markets, the book lays out the evidence for the next economic game changer: the Death of Wealth.

• 

  Lending Works

• 

  Peter Gold

• 

  Jessica K

• 

  Long Over Short